Craig Sauter is a Hematology physician. OpenAlex indexes 491 publications with 11,938 citations (h-index 50); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10201 Carnegie Ave # Ca-60
Cleveland, OH 441062130
Telephone
216-444-2195Provider last certified this registry record 28 Apr 2022.
Clinical trials
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ADC THERAPEUTICS AMERICA, INC.Program year20252 payments
- Genmab U.S., Inc.Program year20252 payments
- BioLineRx USA, Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
30.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor30.5%Acyclovir100%Part D≥27 patientsAnti-infectives
28.4%Short-acting sulfonamides11.3%Sulfamethoxazole-Trimethoprim100%Part D≥12 patientsPenicillins with extended spectrum6.1%Amoxicillin100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
18.3%Corticosteroid10.7%Prednisone100%Part D<11 patientsProton pump inhibitor7.6%Pantoprazole Sodium100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
Journal of Clinical Investigation
2023 - Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Nature Reviews Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”